Positions

Selected Publications

Academic Article

Year Title Altmetric
2023 Syntaxin 1 Ser14 phosphorylation is required for nonvesicular dopamine release.  Science Advances.  9. 2023
2021 Cdk5 drives formation of heterogeneous pancreatic neuroendocrine tumors.  Oncogenesis.  10. 2021
2021 Bile acids gate dopamine transporter mediated currents 2021
2021 Anti-SSTR2 antibody-drug conjugate for neuroendocrine tumor therapy.  Cancer Gene Therapy.  28:799-812. 2021
2021 Cdk5 drives formation of heterogeneous pancreatic neuroendocrine tumors 2021
2021 Psychomotor impairments and therapeutic implications revealed by a mutation associated with infantile Parkinsonism-Dystonia.  eLife.  10. 2021
2020 Phosphoprotein-based biomarkers as predictors for cancer therapy 2020
2018 Preclinical characterization of tyrosine kinase inhibitor-based targeted therapies for neuroendocrine thyroid cancer.  Oncotarget.  9:37662-37675. 2018
2018 Biomimetic nanoparticles with enhanced affinity towards activated endothelium as versatile tools for theranostic drug delivery.  Theranostics.  8:1131-1145. 2018
2014 Regulated localization is sufficient for hormonal control of regulator of G protein signaling homology Rho guanine nucleotide exchange factors (RH-RhoGEFs)..  Journal of Biological Chemistry.  289:19737-19746. 2014
2013 Activated RhoA is a positive feedback regulator of the Lbc family of Rho guanine nucleotide exchange factor proteins..  Journal of Biological Chemistry.  288:11325-11333. 2013

Chapter

Year Title Altmetric
2007 Regulation of Rho guanine nucleotide exchange factors by G proteins..  189-228. 2007

Education And Training

  • Doctor of Philosophy in Cell / Cellular Biology and Anatomical Sciences, The University of Texas Southwestern Medical Center at Dallas 2013

    • Full Name

  • Angela Carter